for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Beigene Ltd

6160.HK

Latest Trade

94.90HKD

Change

-2.00(-2.06%)

Volume

71,500

Today's Range

94.00

 - 

97.05

52 Week Range

69.50

 - 

132.00

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
96.90
Open
97.05
Volume
71,500
3M AVG Volume
3.03
Today's High
97.05
Today's Low
94.00
52 Week High
132.00
52 Week Low
69.50
Shares Out (MIL)
1,008.20
Market Cap (MIL)
97,546.02
Forward P/E
-10.04
Dividend (Yield %)
--

Next Event

Beigene Ltd Annual Shareholders Meeting

Latest Developments

More

Hutchison China MediTech Says Co, Beigene Enter Into Clinical Collaboration

Beigene Announces Acceptance Of Supplemental New Drug Application For Tislelizumab In China

Beigene Says Phase 3 Trial Evaluating Anti-PD-1 Antibody Tislelizumab Met Primary Endpoint

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Beigene Ltd

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

Industry

Biotechnology & Drugs

Contact Info

C/O Mourant Governance Services (Cayman)

94 Solaris Avenue, Camana Bay

KY1-1108

Cayman Islands

+1.345.9494123

Executive Leadership

John Victor Oyler

Co-Founder, Executive Chairman of the Board, Chief Executive Officer

Xiaobin Wu

General Manager - China, President

Xiaodong Wang

Co-Founder, Non-Executive Director

Howard Liang

Chief Financial Officer and Chief Strategy Officer

Jane Huang

Chief Medical Officer, Hematology

Key Stats

1.73 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.2K

2019

0.4K

2020(E)

0.4K
EPS (USD)

2018

-0.930

2019

-1.220

2020(E)

-1.221
Price To Earnings (TTM)
--
Price To Sales (TTM)
31.27
Price To Book (MRQ)
4.48
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
8.91
LT Debt To Equity (MRQ)
8.51
Return on Investment (TTM)
-43.87
Return on Equity (TTM)
-38.81

Latest News

Latest News

BRIEF-Hutchison China MediTech Says Co, Beigene Enter Into Clinical Collaboration

* CHI-MED, BEIGENE ENTER INTO CLINICAL COLLABORATION TO EVALUATE COMBINATIONS OF SURUFATINIB, FRUQUINTINIB WITH TISLELIZUMAB

BRIEF-Beigene And Medison Pharma Announce Exclusive Distribution Agreement And Acceptance Of New Drug Application For Btk Inhibitor Brukinsa™ In Israel

* BEIGENE AND MEDISON PHARMA ANNOUNCE EXCLUSIVE DISTRIBUTION AGREEMENT AND ACCEPTANCE OF NEW DRUG APPLICATION FOR BTK INHIBITOR BRUKINSA™ (ZANUBRUTINIB) IN ISRAEL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-IGM Biosciences, Atreca, Beigene To Collaborate To Help Address Covid-19

* IGM BIOSCIENCES INC - ATRECA, INC. BEIGENE, LTD. AND IGM BIOSCIENCES, INC. ANNOUNCED THEIR PLANS TO COLLABORATE TO HELP ADDRESS COVID-19 PANDEMIC

BRIEF-Beigene Ltd Says CEO John V. Oyler's 2019 Total Compensation Was $12.6 Mln Vs $27.9 Mln In 2018

* BEIGENE LTD - CEO JOHN V. OYLER'S 2019 TOTAL COMPENSATION WAS $12.6 MILLION VERSUS $27.9 MILLION IN 2018 - SEC FILING

BRIEF-Beigene Announces Acceptance Of Supplemental New Drug Application For Tislelizumab In China

* BEIGENE ANNOUNCES ACCEPTANCE OF A SUPPLEMENTAL NEW DRUG APPLICATION FOR TISLELIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN FIRST-LINE ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER IN CHINA

BRIEF-Beigene Says Phase 3 Trial Evaluating Anti-PD-1 Antibody Tislelizumab Met Primary Endpoint

* PHASE 3 TRIAL EVALUATING ANTI-PD-1 ANTIBODY TISLELIZUMAB COMBINED WITH PEMETREXED AND PLATINUM CHEMOTHERAPY MET PRIMARY ENDPOINT

BRIEF-Beigene Announces Positive results from Lung Cancer Trial

* BEIGENE ANNOUNCES THAT THE PHASE 3 TRIAL OF TISLELIZUMAB COMBINED WITH CHEMOTHERAPY IN PATIENTS WITH FIRST-LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER MET THE PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL AT INTERIM ANALYSIS

BRIEF-China Approves Beigene’s Tislelizumab For Patients With Previously Treated Carcinoma

* CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES BEIGENE’S TISLELIZUMAB FOR PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

BRIEF-Beigene Posts FY Net Loss Attributable $948.6 Million

* FY NET LOSS ATTRIBUTABLE $948.6 MILLION VERSUS LOSS OF $673.8 MILLION

BRIEF-Beigene Says Celgene Corp Initiated Voluntary Recall Of All Existing Stock Of Abraxane In Mainland China

* CELGENE CORP INITIATED A VOLUNTARY RECALL OF ALL EXISTING STOCK OF ABRAXANE IN MAINLAND CHINA Further company coverage:

BRIEF-Beigene Announces Supply Update For ABRAXANE In China

* BEIGENE LTD - NMPA HAS SUSPENDED IMPORTATION, SALES AND USE OF ABRAXANE IN CHINA SUPPLIED BY CELGENE CORPORATION

BRIEF-Beigene Ltd Reports 23.7% Stake In Leap Therapeutics Inc As Of March 12, 2020 - SEC Filing

* BEIGENE LTD REPORTS 23.7% STAKE IN LEAP THERAPEUTICS INC AS OF MARCH 12, 2020 - SEC FILING Source : (https://bit.ly/33DsENW) Further company coverage:

BeiGene warns of hit to sales and clinical trials from coronavirus outbreak

China-based drugmaker BeiGene Ltd <6160.HK> <BGNE.O> said on Monday it expects the coronavirus outbreak to impact its operations in China, including sales and clinical trials, particularly in the first quarter.

UPDATE 1-BeiGene warns of hit to sales and clinical trials from coronavirus outbreak

China-based drugmaker BeiGene Ltd said on Monday it expects the coronavirus outbreak to impact its operations in China, including sales and clinical trials, particularly in the first quarter.

BeiGene warns of hit to sales and clinical trials from coronavirus outbreak

BeiGene Ltd said on Monday it expects the coronavirus outbreak to impact its operations in China, including sales and clinical trials, particularly in the first quarter.

BRIEF-Mapkure, Beigene And Springworks Announce Initiation Of Early-Stage Trial Of Refractory Solid Tumors Treatment

* MAPKURE, BEIGENE AND SPRINGWORKS ANNOUNCE INITIATION OF PHASE 1 CLINICAL TRIAL OF BGB-3245, A SELECTIVE NEXT-GENERATION B-RAF INHIBITOR, IN ADULT PATIENTS WITH ADVANCED OR REFRACTORY SOLID TUMORS

UPDATE 1-BeiGene lung cancer treatment improves progression-free survival

China's BeiGene Ltd said on Tuesday its cancer therapy combination helped newly diagnosed lung cancer patients live longer by preventing the disease from progressing, in a late-stage study.

BeiGene lung cancer treatment meets main goal in late-stage study

BeiGene Ltd said on Tuesday its cancer therapy combination for treating lung cancer in previously untreated patients met the main goal in a late-stage study.

BeiGene cancer drug fails in study against AbbVie: J&J's Imbruvica

BeiGene Ltd said on Monday a late-stage trial failed to show that its cancer treatment Brukinsa was superior to Imbruvica, a rival drug from Johnson & Johnson and AbbVie Inc. The results come merely a month after BeiGene scored a win with Brukinsa's approval to treat patients...

BeiGene drug fails main goal in late-stage study against AbbVie-J&J rival Imbruvica

BeiGene Ltd said on Monday a late-stage trial testing its recently approved cancer treatment Brukinsa did not meet the main goal of proving superior to Imbruvica, a rival medicine from Johnson & Johnson and AbbVie Inc.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up